Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study

Fig. 2

Association of FLD with systemic atherosclerosis in participants with common metabolic dysfunction. MD, metabolic dysfunction; FLD, fatty liver disease; PolyVD, polyvascular disease; cOR, common odds ratio; OR, odds ratio; CI, confidence intervals; Adj., adjusted; Ref., reference. All models were adjusted for sex, age, marital status, education, income, current smoking, current drinking, sleep time, sedentary time, family history of ASCVD, eGFR, lipid-lowering medication, antiplatelet medication, and anticoagulants medication. aThe extent of atherosclerotic plaques and stenosis was defined according to the number of 8 vascular sites affected and was divided into four groups, including 0, 1, 2–3, and 4–8 vascular sites. Adjusted cOR and 95% CI were calculated by the ordinary logistic regression model. bPolyVD was defined as the presence of atherosclerotic stenosis in at least two vascular sites. Adjusted OR and 95% CI were calculated by the binary logistic regression model

Back to article page